What is Lifesci Capital’s Estimate for Savara Q2 Earnings?

Savara Inc. (NASDAQ:SVRA) – Equities researchers at Lifesci Capital increased their Q2 2026 EPS estimates for Savara in a research report issued to clients and investors on Sunday, March 15th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s FY2026 earnings at ($0.48) EPS.

SVRA has been the topic of several other research reports. Guggenheim reaffirmed a “buy” rating on shares of Savara in a report on Tuesday, December 23rd. Oppenheimer set a $10.00 price objective on Savara in a research note on Tuesday, December 23rd. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright restated a “buy” rating on shares of Savara in a research note on Monday. Finally, UBS Group set a $10.00 price target on Savara in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Savara Stock Performance

NASDAQ SVRA opened at $5.16 on Wednesday. The company’s 50 day simple moving average is $5.62 and its two-hundred day simple moving average is $5.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 7.65. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The stock has a market capitalization of $1.06 billion, a PE ratio of -9.74 and a beta of 0.31.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Trading of Savara

Institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. lifted its holdings in shares of Savara by 6.9% in the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after acquiring an additional 2,098 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Savara by 3.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after purchasing an additional 2,116 shares in the last quarter. Graham Capital Management L.P. grew its holdings in shares of Savara by 4.9% during the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after purchasing an additional 2,615 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Savara by 9.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after purchasing an additional 2,859 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after purchasing an additional 3,205 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.